Prognostic significance of S-phase fraction detected by antithymidine antibodies in epidermoid cervix carcinomas.
OBJECTIVE
To assess the predictive value of pretreatment proliferative activity of epidermoid cervix carcinoma cells with respect to short- and long-term results of radiotherapy.


METHODS
The proliferative activity of 25 epidermoid cervix carcinomas was evaluated as the immunofluorescent labeling index (LI) by rabbit antithymidine antibodies reacting specifically with single-stranded DNA of replication forks in S-phase cells. The short-term clinical outcome was estimated at 3-6 months after treatment by visual and palpatory examination. Three-year follow-up data were obtained through hospital charts and correspondence with referring physicians for only 19 patients.


RESULTS
There was no statistically significant association between LI and such conventional prognostic factors as clinical stage. The LI value of cervix carcinomas was significantly associated with complete regression at 3-6 months after radiotherapy and 3-year disease-free survival. Complete regression at 3-6 months was observed in 87.5% patients with fast proliferating tumors (LI > 7.0%), and only in 41.2% patients with slowly proliferating tumors (p = 0.03). Probability of 3-year disease-free survival was 85.7% in patients with fast proliferating tumors and 50.0% in those with slowly proliferating tumors (p = 0.05).


CONCLUSIONS
The immunofluorescent LI of epidermoid cervix carcinoma is able to provide prognostic information on short-term tumor response to radiotherapy and disease-free survival.
Zamulaeva
I A
IA
Medical Radiological Research Center, Department of Radiation Biochemistry, Obninsk, Russia.
Podgorodnichenko
V K
VK
Guseva
L I
LI
Krikunova
L I
LI
Saenko
A S
AS
D000328:Adult; D000368:Aged; D000906:Antibodies; D002294:Carcinoma, Squamous Cell / Q000473:pathology* / Q000532:radiotherapy; D002455:Cell Division; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D016196:S Phase; D013936:Thymidine / Q000032:analysis; D002583:Uterine Cervical Neoplasms / Q000473:pathology* / Q000532:radiotherapy
D000906:Antibodies; D013936:Thymidine